Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Pfizer’s Comirnaty Clears Key Panel for Ages 5-11; Actemra Set for COVID-19 Nod
January 21, 2022
-
REGULATORY Macroeconomic Indexing Lacks Perspectives to Promote Innovation, Improve Care: MHLW Bureau Chief
January 20, 2022
-
REGULATORY Re-Pricing to Hit 23 Drugs in April; Takecab, GLP-1s, Vyndaqel/Vynmac, and More
January 19, 2022
-
REGULATORY Takecab Faces 2nd “Huge-Seller” Price Slash, All GLP-1 Injectables to Get Cut Too on Market Expansion
January 18, 2022
-
COMMENTARY Significance and Challenges around Proposed Emergency Approval Scheme, Eyes on Diet Debate
January 17, 2022
-
BUSINESS Pfizer Files Oral COVID-19 Pill in Japan
January 14, 2022
-
REGULATORY Pfizer’s Comirnaty Up for PAFSC Review for Ages 5-11 on Jan. 20; Actemra to Add COVID-19 Use
January 14, 2022
-
BUSINESS Keytruda, Opdivo Neck and Neck in 2021; 6 Drugs Cross 100 Billion Yen Mark: Encise
January 13, 2022
-
REGULATORY AMED to Set Up SCARDA in March to Spearhead Vaccine Development: President
January 12, 2022
-
REGULATORY MHLW Eyes Evaluation Indices and Guidelines to Fuel Rollout of SaMD and Cell & Gene Therapies: Official
January 11, 2022
-
REGULATORY Rewarding Innovation Was the Primary Goal in 2022 Reform Debate: MHLW Official
January 7, 2022
-
REGULATORY MHLW to Reshuffle Organization by Summer to Further Support Drug Development; Economic Affairs Division to Be Renamed
January 7, 2022
-
ORGANIZATION FPMAJ to Go Full Force on Honebuto Debate towards Next Off-Year Price Revision: Chief
January 6, 2022
-
BUSINESS Shionogi’s COVID-19 Pill Submission Delaying into 2022 as Recruitment Hits Snag
January 6, 2022
-
BUSINESS Nexium and Feburic Generic Debuts Eyed in 2022, but with Caution to Avoid Shortages
January 5, 2022
-
REGULATORY Japan Govt to End Observational Avigan Study for COVID-19
January 5, 2022
-
BUSINESS 5 Atopic Dermatitis Drugs Debut in Japan since 2018; Focus Now on Roles of Dupixent, JAK Inhibitors
December 28, 2021
-
TRENDS 15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally
December 28, 2021
-
TRENDS Top 10 PHARMA JAPAN Articles in 2021
December 28, 2021
-
REGULATORY Japan Approves Lenvima/Keytruda Pair, Opdivo Label Expansion
December 27, 2021
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…